A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis

Dig Dis Sci. 2016 Jan;61(1):39-41. doi: 10.1007/s10620-015-3756-z. Epub 2015 Jun 17.

Authors

Ryan B Perumpail¹, Robert J Wong², Edward A Pham¹, John P Higgins³, Tami J Daugherty¹, Aijaz Ahmed⁴

Affiliations

¹ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite # 210, Stanford, CA, 94304, USA.
² Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital Campus, Oakland, CA, USA.
³ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
⁴ Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite # 210, Stanford, CA, 94304, USA. aijazahmed@stanford.edu.

PMID: 26082077
DOI: 10.1007/s10620-015-3756-z

No abstract available

Publication types

Case Reports

MeSH terms

Antiviral Agents / administration & dosage*
Biopsy
Drug Therapy, Combination
End Stage Liver Disease / diagnosis
End Stage Liver Disease / surgery*
End Stage Liver Disease / virology
Hepatitis C / complications
Hepatitis C / diagnosis
Hepatitis C / drug therapy*
Hepatorenal Syndrome / diagnosis
Hepatorenal Syndrome / etiology
Hepatorenal Syndrome / therapy*
Humans
Immunosuppressive Agents / therapeutic use
Kidney Failure, Chronic / diagnosis
Kidney Failure, Chronic / etiology
Kidney Failure, Chronic / therapy*
Liver Transplantation / adverse effects*
Male
Middle Aged
Recurrence
Renal Dialysis*
Simeprevir / administration & dosage
Sofosbuvir / administration & dosage*
Time Factors
Treatment Outcome

Substances

Antiviral Agents
Immunosuppressive Agents
Simeprevir
Sofosbuvir